Steve Arkinstall joins the company as Chief Scientific Officer and Nigel Clark as Head of Business Development
Kymab, a monoclonal antibody biopharmaceutical company based in Cambridge, UK, has appointed Steve Arkinstall as Chief Scientific Officer and Nigel Clark as Vice President and Head of Business Development.
Arkinstall brings more than 25 years’ experience across biopharmaceutical research and development, having worked in several disease areas and specialising in drug target validation, R&D strategic design, antibody discovery and protein engineering. He has joined the company from Merck Serono, where over his 16-year career he held a number of senior management roles including leadership of the Serono Research Institute in Boston, as well as head of Global Technologies and External Innovation. Prior to joining Serono, he was in research at GlaxoWellcome.
Allan Bradley, founder and previously Chief Scientific Officer of Kymab, will continue as a member of the Executive Leadership team. He will serve as Chief Technology Officer driving further advances in Kymab’s proprietary technology platforms, strategic thinking in human population genetics and establishing a vaccine discovery capability. In addition, he will continue as a member of the Board of Directors of Kymab.
Clark has 20 years’ experience in the biopharmaceutical industry at both public and private companies. He was previously Chief Business Officer at Syntaxin and negotiated the sale of the company to Ipsen Pharma for €158m. Prior to this, he was Head of Business Development at Vernalis, where he was responsible for commercial operations, a role he held for seven years.